Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

Inclusion Criteria: * Patients with laboratory-confirmed (PCR) COVID-19 infection * Patients with moderate to severe COVID-19 infection * Hospitalized patients on clinical centers and cantonal hospitals * Patients with radiology-confirmed pneumonia within the clinical condition of COVID-19 infection including pulmonary opacity * Patients with a clinical indication for pneumonia: increased body temperature (defined as a value above ≥ 36.6⁰C axillary route, ≥ 37.2°C oral route or ≥ 37.8 °C rectal route), and/or dyspnea, and/or cough, and/or SpO2 \<96% * Patients aged above 18, both genders * Patients able and willing to understand the study, adhere to all study procedures and sign a written Informed Consent Form (ICF) prior to entering the study or with the assistance of the witness Exclusion Criteria: * Patients not COVID-19 positive * Patients with mild COVID-19 infection * Patients who are study subjects in another clinical study for another investigational agent for COVID-19 * Patients with malignant hypertension * Patients with malignant disease and who are treated for malignant diseases in the last 5 years * Patients with severe liver and kidney insufficiency * Patients who are receiving therapy with an immunomodulatory or immunosuppressive agent * Patients aged below 18, female patients who are pregnant or breastfeeding * Known allergy to study drug or any component thereof * Use of haloperidol, dopamine antagonists, or nonsteroidal anti-inflammatory drugs, except paracetamol.